- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05511480
Reshaping the Motor Engram - An Online Crowdsourcing Study. (FORGET)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- registered Amazon Mechanical Turk users (called 'workers')
- with >95% approval rate on all previous Amazon Mechanical Turk assignments
- location in North America or Europe
- ≥18 years of age
- not having participated in this experiment before
Exclusion Criteria:
• prior participation in this experiment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interference on sequence 1
The interference intervention (session six) will be applied to one of the two previously learned sequences (temporal).
|
Interference through the learning of a competing motor skill.
|
|
Experimental: Interference on sequence 2
The interference intervention (session six) will be applied to one of the two previously learned sequences (spatial).
|
Interference through the learning of a competing motor skill.
|
|
Experimental: Interference on sequences 1 and 2
The interference intervention (session six) will be applied to both of the two previously learned sequences (temporal and spatial).
|
Interference through the learning of a competing motor skill.
|
|
Sham Comparator: No interference
The interference intervention (session six) will be applied.
|
No interference through the continuation of learning same motor skill
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immediate interference rate (change in performance precision)
Time Frame: six days
|
Performance in the learning task is derived from the precision of timing of key presses relative to the occurrence and duration of visual cues presented on the computer screen. The interference rate is operationalized as the change in performance precision over time. The immediate interference effect is analyzed based on the change in performance from before (pre-interference) the interference intervention to directly after the interference intervention in session six (post-interference). This change is normalized to the performance at baseline (pre-interference session six) and computed as [(post-interference - pre-interference)/pre-interference*100]. |
six days
|
|
Delayed interference rate (change in performance precision)
Time Frame: seven days
|
The delayed interference rate is calculated in analogy to the immediate interference effects with a 24-hours latency of the post-interference measure.
Delayed interference is analyzed based on the change in performance from before the interference intervention (pre-interference in session six) to 24 hours after the interference intervention in session seven (24hours post-interference).
This change is normalized to the performance at baseline (pre-interference session six) and computed as [(24 hours post-interference - pre-interference)/pre-interference*100].
|
seven days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Learning rate (change in performance precision)
Time Frame: five days
|
Skill learning is defined based on the precision of timing of key presses relative to the occurrence and duration of visual cues presented on the computer screen.
Skill learning is indexed by increased precision over time, operationalized as declining deviation of key on- and offsets from the timing of cue on- and offsets.
Learning rate is the absolute change of precision over the learning phase of five days, which is expected to follow an asymptotic exponential function.
|
five days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kirstin-Friederike Heise, PhD, Medical University of South Carolina
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 00118731
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Danone NutriciaCompletedHealthy Elderly | Healthy VolunteersChina
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
Clinical Trials on Interference through learning of a competing motor skill.
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Cognitive/Functional EffectsUnited States